BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
HST Global, Inc. HSTC
14 fiscal years on record · USD · FY2023 reported · SEC filings only
$0
$-146,210
Growth
—
Revenue, FY2023 · full 14-year series below
Revenue $
Net income $
FY2023 · Revenue 0.0 · Net income -146210.0
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
Not applicable: equity was negative in this period, so return on equity has no meaning.
The 14-year record
14 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · | · | · | · | · | · | · | · | · | · | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | · | · | −0.03 | −0.04 | 0.13 | −0.07 | 0.00 | 0.00 | −0.01 | −0.01 | −0.01 | −0.01 | −0.01 | −0.03 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Shares out B | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.04 | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 53 reconciliationsAUDITED
Reconciled in 14 of 19 fiscal years. 23 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2010